Elicio reports Phase 2 AMPLIFY-7P results; ITT DFS endpoint not met
Elicio reported that the randomized Phase 2 AMPLIFY-7P trial of camupepimut did not meet its pre-specified primary disease-free survival endpoint in the intent-to-treat population (HR 0.85); the results were presented at ESMO Congress 2026 and published simultaneously in Nature Medicine. Pre-specified subgroup analyses reported hazard ratios of 0.51 in baseline ctDNA-negative patients, 0.57 in ctDNA-positive patients, and 0.59 in patients without prior radiation, while baseline ctDNA positivity was more prevalen...
Read source-backed brief